Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

Submitted by CP Staff on June 21, 2018 - 9:38am
Source: 
Market Realist
News Tags: 
Regeneron
FDA
Eylea
diabetic retinopathy
Headline: 
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
snippet: 

Regeneron (REGN) plans to submit a supplemental biologics license application (or sBLA) to the FDA seeking approval for Eylea in diabetic retinopathy (or DR) without Diabetic Macular Edema (or DME) in late 2018. 

Do Not Allow Advertisers to Use My Personal information